secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001326190-25-000031
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune gets $100M Hercules facility, Q1 cash $150M, MASH data expected Q2 2025
--------------------------------------------------------------------------------

- Up to $100M term loan from Hercules; $15M funded at closing, $25M more in 2025 subject to milestones.
- Interest-only for 24 months (extendable to 42); maturity June 1, 2029; no warrants.
- Q1 net loss of $19.6M ($0.26 loss per share) vs $24.4M loss in Q1 2024.
- Cash, equivalents & short-term investments $150M as of Mar 31, 2025; R&D expense $15.8M.
- Top-line IMPACT Phase 2b MASH data expected Q2 2025; Phase 2 AUD/ALD trials expected Q2/Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000031/0001326190-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000031/alt-20250513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer